“The importance of species selection to predict
the human safety of biopharmaceuticals ”
Thursday 11 May 2017
Janssen Pharmaceuticals, Beerse, Belgium


8:30-9:00 Coffee
9:00-9:10 Welcome
M. Cornet, President of BelTox
Morning session: Lectures
9:10-9:40 Species selection for the non-clinical testing of Biologicals
I Andreini. RTC, Italy
9:40-10:10 Importance of the nonhuman primate in the assessment of Biologicals
S. Grote-Wessels, Covance Munster, Germany
10:10-10:40 Coffee break and networking
10:40-11:05 Alternative approaches to preclinical safety assessment when you have no standard tox species
S. Marshall, Envigo, UK
11:05-11:30 Contribution of immunohistochemistry and tissue cross reactivity to species selection
F. Gervais, CitoxLab, France
11:30-11:55 Are effects in non-clinical species translating into humans ?
A. Cauvin, UCB Biopharma, Belgium
11:55-12:20 Animal models to evaluate vaccine-induced enhanced disease in RSV and other infectious diseases
R. Zahn, J&J, The Netherlands
12:20-12:40 Panel discussion
12:40-13:45 Lunch and networking
Afternoon session: Case studies analysis
13:45-13:55 Introduction to breakout sessions
13:55-15:00 Breakout sessions
15:400-15:30 Coffee break and networking
15:30-16:30 Case study reporting and discussion
16:30-16:40 Concluding remarks

Click here to register

Organizing Committee:
Annick Cauvin and Miranda Cornet (UCB Biopharma), Judith Baumeister and Frédérique Delannois (GSK Vaccines), Miek Desmidt, Ad Knaapen and Kristel Steemans (Johnson & Johnson), Andreas Hohlbaum (Ablynx)

To download the program,  please use the attachment below:

5th Beltox Workshop Safety Assessment Biopharm – 11 May 2017 – Programme